- The Dispatch @ DiscussPharma
- Posts
- Here's what happened in life sciences this past week đź’Šđź“°
Here's what happened in life sciences this past week đź’Šđź“°
General
Why Apple, Amazon, and Google are making big health care moves. Link
Why potentially dodgy diabetes drugs dominate in India. Link
The rising power of oncology clinical data companies. Link
In two months, biotech startups raised more money than in all of 2013. Link
How medicine's long, thin supply chain threatens Americans. Link
Probe into generic drug price fixing set to widen. Link
Merck shells out $300 million to partner Eisai in cancer drug deal. Link
Digital Health
Xbox for Docs: Pharma backs AR games for use in physician learning. Link
How a remote-controlled robotic pill could be the next breakthrough in digital health. Link
Mayo Clinic finds IBM Watson boost in clinical trial enrollment. Link
Research
Immunotherapy: beyond melanoma and lung cancer treatment. Link
Could our blood reveal our future dementia risk? Link
Four stories of antibacterial breakthroughs. Link
Perspective and Opinions
Bringing down the cost of cancer treatment. Link
What will healthcare look like once smart speakers are everywhere? Link
Gene editing could protect endangered species, but it could also change populations and ecosystems in unintended and unstoppable ways bit.ly/2HyFBNI
— WIRED (@WIRED)
2:08 AM • Mar 8, 2018
Interesting
An exercise pill may be in the future for those incapable of working out. Link
How rats could help reduce the global TB burden. Link
Startups of the Week / Notable Deals
Cyteir Therapeutics is targeting diseases with a gain-of-function in AID (Autoimmune disease). The advantages of this gain-of-function approach include potentially broader applicability, reduced side effects, and simpler, sensitive companion diagnostics for patient selection. Closed a $29m Series B financing.
Micropep focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. Raised €4M in Series A funding.
Medial EarlySign provides an advanced AI-based algorithm platform for healthcare organizations to stratify populations to optimize care for individuals and prevent or delay serious health conditions, by leveraging routine blood test results, and common labs and EHR data. Completed a $30m Series B financing
Owlstone Medical is advancing the Breath Biopsy platform for early detection and precision medicine, with applications in cancer and a wide range of other conditions. Raised $15m in funding.